Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How big is the febrile neutropenia market today, and what are its future growth expectations?
The febrile neutropenia market size has grown strongly in recent years. It will grow from $10.60 billion in 2024 to $11.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to the rising incidence of cancer, growing adoption of chemotherapy, expansion of personalized medicine, reducing healthcare costs, and growing prevalence of neutropenia.
The febrile neutropenia market size is expected to see strong growth in the next few years. It will grow to $14.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the growing use of immunosuppressive drugs, increasing R&D, favorable reimbursement policies, increasing investments, rise in incidences of leukemia cases. Major trends in the forecast period include rapid molecular diagnostics, adoption of antimicrobial stewardship & de-escalation therapy, immunotherapy & targeted treatments, risk stratification models, and advancement in fungal biomarkers.
Get Your Free Sample of The Global Febrile Neutropenia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp
What have been the primary factors driving the febrile neutropenia market’s growth?
The increasing prevalence of cancer is expected to propel the growth of the febrile neutropenia market going forward. Cancer is a complex group of diseases characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body. The rising incidence of cancer is due to factors such as an aging population, environmental & occupational exposure, genetic predisposition, and hormonal & reproductive factors. Febrile neutropenia supports cancer patients by highlighting the heightened risk of infections during chemotherapy, prompting early intervention and targeted treatments to prevent life-threatening complications, thereby improving patient outcomes and enabling timely cancer therapy continuation. For instance, in January 2022, according to the American Cancer Society, a US-based cancer awareness non-profit organization, in the US, an estimated 1.9 million new cancer cases and 609,360 cancer-related deaths are expected, reaching up to approximately 1,670 deaths daily. Therefore, the increasing prevalence of cancer is driving the growth of the febrile neutropenia market.
What are the key segments within the febrile neutropenia market?
The febrile neutropenia market covered in this report is segmented –
1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care
2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders
3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections
4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration
Subsegments:
1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems
2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy
3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report
Which key players are shaping the febrile neutropenia market?
Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech
How will emerging trends drive the febrile neutropenia market throughout the forecast period?
Major companies operating in the febrile neutropenia market are focusing on developing advanced biosimilar drugs to enhance treatment accessibility. Biosimilar drugs are biologics that closely resemble approved reference drugs in structure, function, and efficacy. They offer cost-effective alternatives to original biologics, improving patient access while meeting strict regulatory standards. For instance, in September 2022, Fresenius Kabi, a Germany-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for its biosimilar Stimufend (pegfilgrastim-fpgk). This approval allows the use of Stimufend in patients with non-myeloid malignancies who are undergoing myelosuppressive chemotherapy, which can lead to febrile neutropenia, a serious condition characterized by a low white blood cell count and fever. The company plans to launch Stimufend in a prefilled syringe format in early 2023 and is also developing an on-body injector for future use.
How do regional factors impact the febrile neutropenia market, and which region is the largest contributor?
North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Febrile Neutropenia Market Report 2025 Offer?
The febrile neutropenia market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Febrile neutropenia is a medical condition characterized by a fever (temperature of 100.4°F or higher) and a low number of neutrophils, which are a type of white blood cell essential for fighting infections. This condition is often seen in patients undergoing chemotherapy or other treatments that suppress the immune system, making them more vulnerable to infections.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21187
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
